Fulcrum therapeutics reports inducement grants under nasdaq listing rule 5635(c)(4)

Cambridge, mass., dec. 05, 2022 (globe newswire) -- fulcrum therapeutics, inc.® (nasdaq: fulc), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to new employees.

FULC Ratings Summary

FULC Quant Ranking